Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Ibere Pharmaceuticals Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 11/14/2022 | Q3 2022 | N/A | $0.11 | N/A | N/A | $0 |
| 08/12/2022 | Q2 2022 | N/A | $0.18 | N/A | N/A | $0 |
| 05/16/2022 | Q1 2022 | N/A | $0.43 | N/A | N/A | $0 |
| 03/31/2022 | Q4 2021 | N/A | $0.07 | N/A | N/A | $0 |
| 11/12/2021 | Q3 2021 | N/A | $0.10 | N/A | N/A | $0 |
| 08/16/2021 | Q2 2021 | N/A | -$0.03 | N/A | N/A | $0 |
| 07/16/2021 | Q1 2021 | N/A | -$0.03 | N/A | N/A | $0 |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Ibere Pharmaceuticals Earnings: FAQ's
Ibere Pharmaceuticals has not confirmed its next earnings publication date, but the company's estimated earnings date is Monday, March 6th, 2023 based offlast year's report dates.
The conference call for Ibere Pharmaceuticals's latest earnings report can be listened to online.
The conference call transcript for Ibere Pharmaceuticals's latest earnings report can be read online.
Ibere Pharmaceuticals (:IBER) has a recorded net income of $1.56 M.Ibere Pharmaceuticals has generated $0.34 earnings per share over the last four quarters.
Ibere Pharmaceuticals (:IBER) has a price-to-earnings ratio of 96.92 and price/earnings-to-growth ratio is 0.97.